L04AA32 · Antineoplastic and immunomodulating agents
Apremilast Viatris
Indications
Treatment of psoriatic arthritis, psoriasis, Behçet’s disease.
Composition
- Active substance
- apremilast
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Apremilast Viatris
- Active substance
- apremilast
- ATC code
- L04AA32
- Therapeutic area
- Arthritis, Psoriatic, Psoriasis, Behcet Syndrome
- Marketing authorisation holder
- Viatris Limited
- Status
- Application withdrawn
- EMA product number
- EMEA/H/C/006193